Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT2 | O75908 | 4/20 | 0.46 |
| ▸ | SOAT1 | P35610 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | STAT1 | P42224 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25763347 | 1.00 | SOAT2 (0.46) | SOAT2SOAT1KMT2AGAAL3MBTL1 | |
| SCHEMBL21774349 | 0.86 | MAPT (0.47) | KMT2AGAAL3MBTL1LMNASTAT1 | |
| SCHEMBL21774381 | 0.85 | KMT2A (0.51) | KMT2AGAAL3MBTL1LMNASTAT1 | |
| SCHEMBL21775898 | 0.83 | SOAT2 (0.51) | SOAT2SOAT1KMT2AL3MBTL1LMNA | |
| SCHEMBL21775901 | 0.83 | SOAT2 (0.51) | SOAT2SOAT1KMT2AL3MBTL1LMNA | |
| SCHEMBL25763260 | 0.82 | SOAT2 (0.43) | SOAT2SOAT1KMT2AGAAL3MBTL1 | |
| SCHEMBL21774371 | 0.82 | SOAT2 (0.43) | SOAT2SOAT1KMT2AGAAL3MBTL1 | |
| SCHEMBL21774133 | 0.81 | MAPT (0.49) | KMT2AGAAL3MBTL1LMNASTAT1 | |
| SCHEMBL21774377 | 0.81 | KLK6 (0.55) | KMT2AGAAL3MBTL1LMNASTAT1 | |
| SCHEMBL21774330 | 0.79 | KMT2A (0.59) | KMT2AGAAL3MBTL1LMNASTAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11692004-B2 | Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof | JIANGSU VANGUARD PHARMACEUTICAL CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-11692004-B2 | Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof | JIANGSU VANGUARD PHARMACEUTICAL CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| WO-2020038279-A1 | SUBSTITUTED PYRAZOLE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | 天津谷堆生物医药科技有限公司 | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11692004-B2 | Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof | FARS2, GOT2, HADHB | SOAT2 1946/4885SOAT1 2134/4885KMT2A 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.